Evaluation of Retinal Microvascular Changes in Central Retinal Vein Occlusion by Using Optical Coherence Tomography Angiography before and after Anti-VEGF therapy (Ranibizumab)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202512755596999

Enrollment

Registered

2025-12-05

Start date

2024-01-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

OCTA before and after intravitreai injection of Ranibizumab in patients with CRVO

OCTA in assessment of healthy eyes of patients with CRVO

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients older than 18 years, had a diagnosis of CRVO with macular edema exhibited a central macular thickness (CMT) of 300 microns or greater.

Exclusion criteria

Exclusion criteria: the presence of other ocular diseases such as diabetic retinopathy, retinal artery occlusion, or age-related macular degeneration, any significant media opacity a prior history of retinal laser photocoagulation previous anti-VEGF therapy

Design outcomes

Primary

Measure	Time frame
FAZ area, superfescial vessel density, Deep Vessel Density	—

Secondary

Measure	Time frame
Central Retinal Thickness Best-Corrected Visual Acuity	—

Countries

Egypt

Contacts

Public ContactAshraf Gadelkareem

Professor of Ophthalmology

Ashraf.GadElkareem@azhar.edu.eg+201060293796

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026